4.7 Review

Semaglutide for the treatment of overweight and obesity: A review

期刊

DIABETES OBESITY & METABOLISM
卷 25, 期 1, 页码 18-35

出版社

WILEY
DOI: 10.1111/dom.14863

关键词

anti-obesity drug; GLP-1 analogue; obesity therapy; weight management

向作者/读者索取更多资源

Obesity is a chronic disease with various complications and a significant impact on morbidity, mortality, and healthcare burden. The Semaglutide Treatment Effect in People with obesity (STEP) clinical trial program has shown that the use of once-weekly subcutaneous semaglutide 2.4 mg can lead to substantial weight loss in individuals with overweight or obesity. The trials demonstrated a mean weight loss of 14.9%-17.4% and a high proportion of participants achieving a weight loss of 10% or more with semaglutide 2.4 mg.
Obesity is a chronic, relapsing disease associated with multiple complications and a substantial morbidity, mortality and health care burden. Pharmacological treatments for obesity provide a valuable adjunct to lifestyle intervention, which often achieves only limited weight loss that is difficult to maintain. The Semaglutide Treatment Effect in People with obesity (STEP) clinical trial programme is evaluating once-weekly subcutaneous semaglutide 2.4 mg (a glucagon-like peptide-1 analogue) in people with overweight or obesity. Across STEP 1, 3, 4 and 8, semaglutide 2.4 mg was associated with mean weight losses of 14.9%-17.4% in individuals with overweight or obesity without type 2 diabetes from baseline to week 68; 69%-79% of participants achieved >= 10% weight loss with semaglutide 2.4 mg (vs. 12%-27% with placebo) and 51%-64% achieved >= 15% weight loss (vs. 5%-13% with placebo). In STEP 5, mean weight loss was -15.2% with semaglutide 2.4 mg versus -2.6% with placebo from baseline to week 104. In STEP 2 (individuals with overweight or obesity, and type 2 diabetes), mean weight loss was -9.6% with semaglutide 2.4 mg versus -3.4% with placebo from baseline to week 68. Improvements in cardiometabolic risk factors, including high blood pressure, atherogenic lipids and benefits on physical function and quality of life were seen with semaglutide 2.4 mg. The safety profile of semaglutide 2.4 mg was consistent across trials, primarily gastrointestinal adverse events. The magnitude of weight loss reported in the STEP trials offers the potential for clinically relevant improvement for individuals with obesity-related diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据